FDA approves new IV flu drug

The FDA has approved Biocryst's RAPIVAB drug to help treat the flu.

DURHAM, N.C. (WNCN) – In the midst of a major Tamiflu shortage nationwide, Triangle-based BioCryst may have a solution with its newly FDA approved drug RAPIVAB.

The drug has been approved for acute cases of the flu in patients 18 years of age and older and for those patients who have only shown signs of flu-like symptoms for no more than two days.

“In a blinded, randomized placebo-controlled trial, a single dose of RAPIVAB alleviated flu symptoms, and reduced fever significantly faster than placebo,” said Richard Whitley, M.D., University of Alabama at Birmingham.

According to BioCryst, this is the first new antiviral treatment for the flu that the FDA has approved in 15 years.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s